Rhythm Pharma reports preliminary 2024 IMCIVREE sales of $130M, up 68% YoY; Phase 3 HO data on track for H1 2025

RHYTHM PHARMACEUTICALS, INC.

Preliminary Q4 2024 IMCIVREE net revenues of ~$42M, up 26% sequentially; full year ~$130M vs $77.4M in 2023.
U.S. sales contributed ~74% of Q4 and ~73% of full year 2024 revenues.
Topline data from Phase 3 acquired hypothalamic obesity trial expected in first half of 2025; completed Japanese cohort.
Phase 3 EMANATE enrollment completed across four substudies; topline data anticipated first half of 2026.
New Phase 2 trial of setmelanotide in Prader-Willi syndrome to initiate Q1 2025 (up to 20 patients, 26 weeks).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.